NCT06853145 Hyperpolarized Xenon-129 MRI in Idiopathic Pulmonary Fibrosis
| NCT ID | NCT06853145 |
| Status | Recruiting |
| Phase | EARLY_Phase 1 |
| Sponsor | University of Virginia |
| Condition | Idiopathic Pulmonary Fibrosis |
| Study Type | INTERVENTIONAL |
| Enrollment | 6 participants |
| Start Date | 2025-05-01 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 6 participants in total. It began in 2025-05-01 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Idiopathic pulmonary fibrosis has a poor prognosis with limited treatment options. The Investigator hypothesize hyperpolarized Xe129-MRI can be performed in patients with IPF and repeated over time which will detect deficiencies related to perfusion in the lung.
Eligibility Criteria
Inclusion Criteria: * Able to provide informed consent 18 years of age or greater Clinical diagnosis of IPF Exclusion Criteria: * Continuous oxygen use at home * Oxygen saturation less than 92% on the day of MRI procedure * Pregnancy or lactation * Claustrophobia, inner ear implants, aneurysm or other surgical clips, metal foreign bodies in eye, pacemaker or other contraindication to MR scanning. Subjects with any implanted device that cannot be verified as MRI compliant will be excluded. * History of congenital cardiac disease, chronic renal failure, or cirrhosis. • Chest circumference greater than that of the xenon MR and/or helium coil. The circumference of the coil is approximately 42 inches. * Inability to understand simple instructions or to hold still for approximately 10-15 seconds. * History of respiratory infection within 2 weeks prior to the MR scan * History of MI, stroke and/or poorly controlled hypertension.
Contact & Investigator
John Kim, MD
PRINCIPAL INVESTIGATOR
University of Virginia
Frequently Asked Questions
Who can join the NCT06853145 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Idiopathic Pulmonary Fibrosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06853145 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06853145 currently recruiting?
Yes, NCT06853145 is actively recruiting participants. Contact the research team at rnn3b@uvahealth.org for enrollment information.
Where is the NCT06853145 trial being conducted?
This trial is being conducted at Charlottesville, United States.
Who is sponsoring the NCT06853145 clinical trial?
NCT06853145 is sponsored by University of Virginia. The principal investigator is John Kim, MD at University of Virginia. The trial plans to enroll 6 participants.